U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Refractory Adrenal Gland Pheochromocytoma

MedGen UID:
1673295
•Concept ID:
C4764217
•
Neoplastic Process

Definition

A pheochromocytoma that does not respond to treatment. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRefractory Adrenal Gland Pheochromocytoma

Professional guidelines

PubMed

The diagnosis and management of pheochromocytoma and paraganglioma during pregnancy.
Clifton-Bligh RJ
Rev Endocr Metab Disord 2023 Feb;24(1):49-56. Epub 2023 Jan 13 doi: 10.1007/s11154-022-09773-2. PMID: 36637675Free PMC Article
Recent advances in the management of pheochromocytoma and paraganglioma.
Tanabe A, Naruse M
Hypertens Res 2020 Nov;43(11):1141-1151. Epub 2020 Aug 11 doi: 10.1038/s41440-020-0531-0. PMID: 32778780
Pathophysiology and Acute Management of Tachyarrhythmias in Pheochromocytoma: JACC Review Topic of the Week.
Nazari MA, Rosenblum JS, Haigney MC, Rosing DR, Pacak K
J Am Coll Cardiol 2020 Jul 28;76(4):451-464. doi: 10.1016/j.jacc.2020.04.080. PMID: 32703516Free PMC Article

Recent clinical studies

Etiology

Prognostic factors for refractory pheochromocytoma and paraganglioma after (131)I-metaiodobenzylguanidine therapy.
Hiromasa T, Wakabayashi H, Kayano D, Inaki A, Watanabe S, Mori H, Akatani N, Yamase T, Kunita Y, Saito S, Kinuya S
Ann Nucl Med 2022 Jan;36(1):61-69. Epub 2021 Oct 13 doi: 10.1007/s12149-021-01685-6. PMID: 34647244
Takotsubo syndrome and pheochromocytoma: an insidious combination.
Maffè S, Dellavesa P, Paffoni P, Bergamasco L, Arrondini M, Valentini S, Facchini E, Prenna E, Baduena L, Careri G, Franchetti Pardo N, Parravicini U
Monaldi Arch Chest Dis 2021 Mar 9;91(3) doi: 10.4081/monaldi.2021.1711. PMID: 33691391
Life-threatening events in patients with pheochromocytoma.
Riester A, Weismann D, Quinkler M, Lichtenauer UD, Sommerey S, Halbritter R, Penning R, Spitzweg C, Schopohl J, Beuschlein F, Reincke M
Eur J Endocrinol 2015 Dec;173(6):757-64. Epub 2015 Sep 7 doi: 10.1530/EJE-15-0483. PMID: 26346138
Phaeochromocytoma: state-of-the-art.
Donckier JE, Michel L
Acta Chir Belg 2010 Mar-Apr;110(2):140-8. doi: 10.1080/00015458.2010.11680587. PMID: 20514823
Colorectal manifestations of endocrine disease.
Sharma S, Longo WE, Baniadam B, Vernava AM 3rd
Dis Colon Rectum 1995 Mar;38(3):318-23. doi: 10.1007/BF02055611. PMID: 7882801

Diagnosis

The diagnosis and management of pheochromocytoma and paraganglioma during pregnancy.
Clifton-Bligh RJ
Rev Endocr Metab Disord 2023 Feb;24(1):49-56. Epub 2023 Jan 13 doi: 10.1007/s11154-022-09773-2. PMID: 36637675Free PMC Article
Prognostic factors for refractory pheochromocytoma and paraganglioma after (131)I-metaiodobenzylguanidine therapy.
Hiromasa T, Wakabayashi H, Kayano D, Inaki A, Watanabe S, Mori H, Akatani N, Yamase T, Kunita Y, Saito S, Kinuya S
Ann Nucl Med 2022 Jan;36(1):61-69. Epub 2021 Oct 13 doi: 10.1007/s12149-021-01685-6. PMID: 34647244
Recent advances in the management of pheochromocytoma and paraganglioma.
Tanabe A, Naruse M
Hypertens Res 2020 Nov;43(11):1141-1151. Epub 2020 Aug 11 doi: 10.1038/s41440-020-0531-0. PMID: 32778780
Metastatic pheochromocytoma and paraganglioma.
Angelousi A, Kassi E, Zografos G, Kaltsas G
Eur J Clin Invest 2015 Sep;45(9):986-97. doi: 10.1111/eci.12495. PMID: 26183460
Phaeochromocytoma: state-of-the-art.
Donckier JE, Michel L
Acta Chir Belg 2010 Mar-Apr;110(2):140-8. doi: 10.1080/00015458.2010.11680587. PMID: 20514823

Therapy

Pheochromocytoma crisis with refractory Acute Respiratory Distress Syndrome (ARDS), Takotsubo syndrome, emergency adrenalectomy, and need for Extracorporeal Membrane Oxygenation (ECMO) in a previously undiagnosed and asymptomatic patient, due to the use of metoclopramide.
Xie Y, Zhang A, Qi M, Xiong B, Zhang S, Zhou J, Cao Y
BMC Endocr Disord 2023 Jul 10;23(1):145. doi: 10.1186/s12902-023-01404-4. PMID: 37430225Free PMC Article
An open-label, single-arm, multi-center, phase II clinical trial of single-dose [(131)I]meta-iodobenzylguanidine therapy for patients with refractory pheochromocytoma and paraganglioma.
Inaki A, Shiga T, Tsushima Y, Jinguji M, Wakabayashi H, Kayano D, Akatani N, Yamase T, Kunita Y, Watanabe S, Hiromasa T, Mori H, Hirata K, Watanabe S, Higuchi T, Tomonaga H, Kinuya S
Ann Nucl Med 2022 Mar;36(3):267-278. Epub 2021 Dec 6 doi: 10.1007/s12149-021-01699-0. PMID: 34870794Free PMC Article
Prognostic factors for refractory pheochromocytoma and paraganglioma after (131)I-metaiodobenzylguanidine therapy.
Hiromasa T, Wakabayashi H, Kayano D, Inaki A, Watanabe S, Mori H, Akatani N, Yamase T, Kunita Y, Saito S, Kinuya S
Ann Nucl Med 2022 Jan;36(1):61-69. Epub 2021 Oct 13 doi: 10.1007/s12149-021-01685-6. PMID: 34647244
A phase I clinical trial for [(131)I]meta-iodobenzylguanidine therapy in patients with refractory pheochromocytoma and paraganglioma.
Wakabayashi H, Inaki A, Yoshimura K, Murayama T, Imai Y, Higuchi T, Jinguji M, Shiga T, Kinuya S
Sci Rep 2019 May 20;9(1):7625. doi: 10.1038/s41598-019-43880-6. PMID: 31110198Free PMC Article
A phase I clinical trial for [(131)I]meta-iodobenzylguanidine therapy in patients with refractory pheochromocytoma and paraganglioma: a study protocol.
Inaki A, Yoshimura K, Murayama T, Imai Y, Kuribayashi Y, Higuchi T, Jinguji M, Shiga T, Kinuya S
J Med Invest 2017;64(3.4):205-209. doi: 10.2152/jmi.64.205. PMID: 28954983

Prognosis

An open-label, single-arm, multi-center, phase II clinical trial of single-dose [(131)I]meta-iodobenzylguanidine therapy for patients with refractory pheochromocytoma and paraganglioma.
Inaki A, Shiga T, Tsushima Y, Jinguji M, Wakabayashi H, Kayano D, Akatani N, Yamase T, Kunita Y, Watanabe S, Hiromasa T, Mori H, Hirata K, Watanabe S, Higuchi T, Tomonaga H, Kinuya S
Ann Nucl Med 2022 Mar;36(3):267-278. Epub 2021 Dec 6 doi: 10.1007/s12149-021-01699-0. PMID: 34870794Free PMC Article
Prognostic factors for refractory pheochromocytoma and paraganglioma after (131)I-metaiodobenzylguanidine therapy.
Hiromasa T, Wakabayashi H, Kayano D, Inaki A, Watanabe S, Mori H, Akatani N, Yamase T, Kunita Y, Saito S, Kinuya S
Ann Nucl Med 2022 Jan;36(1):61-69. Epub 2021 Oct 13 doi: 10.1007/s12149-021-01685-6. PMID: 34647244
A phase I clinical trial for [(131)I]meta-iodobenzylguanidine therapy in patients with refractory pheochromocytoma and paraganglioma.
Wakabayashi H, Inaki A, Yoshimura K, Murayama T, Imai Y, Higuchi T, Jinguji M, Shiga T, Kinuya S
Sci Rep 2019 May 20;9(1):7625. doi: 10.1038/s41598-019-43880-6. PMID: 31110198Free PMC Article
A phase I clinical trial for [(131)I]meta-iodobenzylguanidine therapy in patients with refractory pheochromocytoma and paraganglioma: a study protocol.
Inaki A, Yoshimura K, Murayama T, Imai Y, Kuribayashi Y, Higuchi T, Jinguji M, Shiga T, Kinuya S
J Med Invest 2017;64(3.4):205-209. doi: 10.2152/jmi.64.205. PMID: 28954983
Metastatic pheochromocytoma and paraganglioma.
Angelousi A, Kassi E, Zografos G, Kaltsas G
Eur J Clin Invest 2015 Sep;45(9):986-97. doi: 10.1111/eci.12495. PMID: 26183460

Clinical prediction guides

An open-label, single-arm, multi-center, phase II clinical trial of single-dose [(131)I]meta-iodobenzylguanidine therapy for patients with refractory pheochromocytoma and paraganglioma.
Inaki A, Shiga T, Tsushima Y, Jinguji M, Wakabayashi H, Kayano D, Akatani N, Yamase T, Kunita Y, Watanabe S, Hiromasa T, Mori H, Hirata K, Watanabe S, Higuchi T, Tomonaga H, Kinuya S
Ann Nucl Med 2022 Mar;36(3):267-278. Epub 2021 Dec 6 doi: 10.1007/s12149-021-01699-0. PMID: 34870794Free PMC Article
Prognostic factors for refractory pheochromocytoma and paraganglioma after (131)I-metaiodobenzylguanidine therapy.
Hiromasa T, Wakabayashi H, Kayano D, Inaki A, Watanabe S, Mori H, Akatani N, Yamase T, Kunita Y, Saito S, Kinuya S
Ann Nucl Med 2022 Jan;36(1):61-69. Epub 2021 Oct 13 doi: 10.1007/s12149-021-01685-6. PMID: 34647244
Recent advances in the management of pheochromocytoma and paraganglioma.
Tanabe A, Naruse M
Hypertens Res 2020 Nov;43(11):1141-1151. Epub 2020 Aug 11 doi: 10.1038/s41440-020-0531-0. PMID: 32778780
A phase I clinical trial for [(131)I]meta-iodobenzylguanidine therapy in patients with refractory pheochromocytoma and paraganglioma.
Wakabayashi H, Inaki A, Yoshimura K, Murayama T, Imai Y, Higuchi T, Jinguji M, Shiga T, Kinuya S
Sci Rep 2019 May 20;9(1):7625. doi: 10.1038/s41598-019-43880-6. PMID: 31110198Free PMC Article
Metastatic pheochromocytoma and paraganglioma.
Angelousi A, Kassi E, Zografos G, Kaltsas G
Eur J Clin Invest 2015 Sep;45(9):986-97. doi: 10.1111/eci.12495. PMID: 26183460

Recent systematic reviews

Extracorporeal life support for phaeochromocytoma-induced cardiogenic shock: a systematic review.
Matteucci M, Kowalewski M, Fina D, Jiritano F, Meani P, Raffa GM, Aldobayyan I, Beghi C, Maessen J, Lorusso R
Perfusion 2020 May;35(1_suppl):20-28. doi: 10.1177/0267659120908413. PMID: 32397890

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...